Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0H3HM
|
|||
| Former ID |
DAP000076
|
|||
| Drug Name |
Aripiprazole
|
|||
| Synonyms |
129722-12-9; Abilify; Abilitat; Abilify Discmelt; OPC-14597; Discmelt; Opc 14597; OPC 31; OPC-31; 7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril; UNII-82VFR53I78; C23H27Cl2N3O2; HSDB 7320; 7-(4-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)BUTOXY)-3,4-DIHYDROQUINOLIN-2(1H)-ONE; CHEMBL1112; 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one; 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone; CHEBI:31236; Abilify; Aripiprazol; Aripiprazolum; Aripirazole; Arpizol; Asprito; Pripiprazole; Aripiprazole [USAN]; Otsuka brand of aripiprazole; OPC 14597; ALKS-9070; Abilify (TN); BMS-337039; Bristol-Myers Squibb brand of aripiprazole; Discmelt (TN); KS-1030; S06-0010; Aripiprazole (JAN/USAN/INN); 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-2(1H)-quinolinone; 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril; 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one; 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one; ALKS9070/ALKS9072; Aripiprazole/escitalopram fixed-dose combination
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Erythropoietic porphyrias [ICD-11: 5C58.12; ICD-10: E80.0] | Approved | [1] | |
| Schizophrenia [ICD-11: 6A20] | Approved | [2], [3] | ||
| Major depressive disorder [ICD-11: 6A70.3; ICD-10: F32.2] | Phase 3 | [4] | ||
| Bipolar disorder [ICD-11: 6A60; ICD-10: F31] | Application submitted | [5] | ||
| Therapeutic Class |
Antipsychotic Agents
|
|||
| Company |
Bristol-Myers Squibb; Otsuka Pharmaceutical Co., Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H27Cl2N3O2
|
|||
| Canonical SMILES |
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl
|
|||
| InChI |
1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)
|
|||
| InChIKey |
CEUORZQYGODEFX-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 129722-12-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
582954, 7848227, 7978512, 8187059, 11528738, 12014488, 14759758, 15103350, 25819894, 26719891, 29215485, 29215486, 43118141, 46386763, 46505745, 49658671, 49666283, 49666418, 49681659, 49830718, 57314118, 77392862, 81042514, 81065479, 81092781, 85202210, 85209988, 89736075, 92307952, 92308408, 92308936, 92713933, 103307946, 104021727, 104321668, 117470150, 117868935, 118048569, 124365869, 124658892, 124799564, 125001911, 125339803, 126525334, 126592371, 126624438, 126655782, 126669992, 126728368, 127275956
|
|||
| ChEBI ID |
CHEBI:31236
|
|||
| ADReCS Drug ID | BADD_D00165 | |||
| SuperDrug ATC ID |
N05AX12
|
|||
| SuperDrug CAS ID |
cas=129722129
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Parabacteroides distasonis
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Parabacteroides distasonis was decreased by Aripiprazole (adjusted p-values: 1.88E-04). | |||
|
Studied Microbe: Prevotella copri
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Prevotella copri was decreased by Aripiprazole (adjusted p-values: 8.49E-03). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Enterocloster bolteae
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Enterocloster bolteae was decreased by Aripiprazole (adjusted p-values: 2.54E-03). | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 34). | |||
| REF 3 | Electrophysiological studies in the rat brain on the basis for aripiprazole augmentation of antidepressants in major depressive disorder. Psychopharmacology (Berl). 2009 Oct;206(2):335-44. | |||
| REF 4 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034267) | |||
| REF 5 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 6 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 7 | Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert Opin Investig Drugs. 2007 Jun;16(6):771-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.